SOURCES http://www.marketwatch.com/investing/stock/cybx/profile Cyberonics, Inc. engages in the design, development, marketing, and sale of implantable medical devices.

It offers vagus nerve stimulation therapy ( !" #herapy$. It sells its products directly, as well as through independent distributors in %urope, Canada, &exico, 'ustralia, parts of Central and "outh 'merica, the &iddle %ast, China, (apan, and other parts of 'sia. #he company was founded in )*+, and is head-uartered in .ouston, #exas. http://www.marketwatch.com/story/)/0-0cyberonics0inc01/)10))0)* #he 23' approved our !" #herapy "ystem in (uly )**, for use as an ad4unctive therapy in epilepsy patients over )1 years of age in reducing the fre-uency of partial onset sei5ures that are refractory or resistant to antiepileptic drugs. In (uly 1//6, the 23' approved the !" #herapy "ystem for the ad4unctive long0term treatment of chronic or recurrent depression for patients )+ years of age or older who are experiencing a ma4or depressive episode and have not had an ade-uate response to four or more ade-uate anti0depressant treatments. In order to accommodate expected growth of our business, we have created the following subsidiaries: Cyberonics .oldings 77C, C89: !etherlands C. ., Cyberonics "pain, ".7. and Cyberonics 7atam ".;.7. In "eptember 1/)1, our new subsidiary, Cyberonics, 7atam ".;.7., contracted to purchase land and construct a manufacturing facility in Costa ;ica. <e intend for this facility to manufacture product for our international markets and to be completed in fiscal year 1/)= and operational in fiscal year 1/)6. http://ir.cyberonics.com/releasedetail.cfm>;eleaseI3?,/+@A* .BC"#B!, "ept. 1/, 1/)1 /D;!ewswire/ 00 Cyberonics, Inc. (C89:$, a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of E 1 million in cerbomed Fmb. (GcerbomedG$. 9ased in %rlangen, Fermany, cerbomed is a privately0held company developing a non0invasive neurostimulation device for the treatment of epilepsy. #he !%&B"H t0 !" device received C% &ark approval for the treatment of epilepsy and depression in 1/)/ and for pain in 1/)1 and is now commercially available in Fermany and 'ustria. http://seekingalpha.com/news0article/@)@6==)0cyberonics0announces0license0agreement0with0 imricor0medical0systems0for0mri0compatibility0lead0technology .BC"#B!, (une )), 1/)1 /D;!ewswire/ 00 Cyberonics, Inc. (C89:$ today announced that it has entered into an exclusive technology license agreement with Imricor &edical "ystems, Inc. to develop &agnetic ;esonance Imaging (G&;IG$ compatible leads for use with the !" #herapyH "ystem ( agus !erve "timulation$.Imricor &edical "ystems, based in 9urnsville, &innesota, is developing innovative &;I electrophysiology tools and has developed the worldIs

only ablation catheter that is designed for use with &;I systems in %D procedures 0 the isionG catheterJ. http://finance.yahoo.com/news/cyberonic0ventures0germany0)+)=1,/)*.html #he recent <orld .ealth Brgani5ation study on %pilepsy also revealed that there are over @./ million individuals with epilepsy in <estern %urope, with over )6/,/// new cases diagnosed each year. http://wallstreetpr.com/cyberonics0nasda-cybx0cheers0on0satisfy0-uarter0profit0cybx0bsx0mdt0 st40holx0=616 #he C89: return on investment was recorded as 1).*6K as compare to its rivals has 9oston "cientific Corporation (!8"%:9":$Ls ;BI 01@.)+K, &edtronic, Inc. (!8"%:&3#$Ls ;BI )1.++K, "t. (ude &edical, Inc. (!8"%:"#($Ls ;BI *.,/K, .ologic, Inc. (!'"3'M:.B7:$Ls ;BI 0/.*AK. !otable 'nalystsL ;ecommendations for &onday (C89:, 3!;, 2!2, &%3, <"&$ Canaccord Fenuity raises target price for Cyberonics Inc. (!'"3'M:C89:$ to N6, from N6A after the company reported second0-uarter results above estimates, driven by strong outside C.". epilepsy revenues and better0than0expected C.". epilepsy revenue

ARTICLE It is the seventh consecutive -uarter that Cyberonics Inc. has reported a ma4or increase in their income and this has been translating well for the company in terms of shares and stock activity. 8early revenue reports from Cyberonics also pro4ect notably outstanding results with a =0year upward trend in profits. <ith this excellent performance exhibited by Cyberonics in the market, and with recent developments and innovations by the company in the field of medicine, investors will be looking at a good long0term venture. Cyberonics Inc. is a revolutionary medical technology company that is engaged in the creation, production, improvement and distribution of implantable medical devices, especially in the field of neuromodulation. Cpon its establishment in )*+,, Cyberonics have expanded its sphere of influence in various continents by direct and independent distributions and by establishing subsidiaries in 'merica, %urope, 'ustralia, ;ussia and 'sia (including #aiwan, (apan and China$. "ome of the subsidiaries created by Cyberonics across the globe are Cyberonics .oldings 77C, C89: !etherlands C. ., Cyberonics "pain, ".7. and Cyberonics 7atam ".;.7. in 7atin 'merica that would handle the construction of the soon0to0open manufacturing facility in Costa ;ica, fiscal 1/)6. Completion of the said facility would ensure regulatory flexibility and maximum efficiency with regards to the companyIs international manufacturing and sales. In its most recent -uarterly release, Cyberonics reported an excellent ),K boost in its net sales from last -uarter. Bne of the ma4or factors that contributed to this outstanding performance is the continous efforts of the company to develop its products, especially its trademarked !" #herapy "ystem. !" #herapy utili5es an implantable pulse generator that has been approved by the 2ood and 3rug 'uthority and various regulatory boards across the globe for the treatment of refractory epilepsy. In 1//6, the 23' approved the use of !" #herapy also for patients suffering with chronic and recurring depression. #he company continues to improve, not only its international efforts, but also the -uality of its !" #herapy "ystem with the partnerships and investments it engages in. Cyberonics announced recently a licence agreement with Imricor &edical "ystems, Inc., a company based in &innesota that is the lead innovator in &agnetic ;esonance Imaging (&;I$ electrophysiology tools. Cyberonics also declared a huge E1 million investment in cerbomed Fmb., a privately0 held medical device company based on Fermany that is also into development of neurostimulation devices for epilepsy treatment. #his venture by Cyberonics is expected to generate fruitful results as it would extend the influence of the company to greater %uropean countries as the !%&B"H t0 !" device is now commercially available in 'ustralia and Fermany. <ith a tremendous amount of @ million individuals who are suffering with epilepsy in <estern %urope, as according to the <orld .ealth Brgani5ation (<.B$, this endeavor by Cyberonics in the %uropean market would translate to good profit. #his was proven in the companyLs fiscal 1/)@ report of international net sales increase to N)).) million from fiscal 1/)1Ls N+.A million. 'part from promising international performance, investors should be looking out for the companyLs ;eturns on Investment (;BI$ measure. %ven as a small cap company, Cyberonics rates second in terms of ;BI measure with 1).*6K compared to its rival companies like

&edtronic, Inc. at )1.++K, "t. (ude &edical, Inc. at *.,/K and .ologic, Inc. at a negative /.*AK. 'nother interesting thing to note about Cyberonics is its standing of N6) in the market, a high price compared to other companies in the medical sector like 9oston "cientific Corp. at N6, Cynosure, Inc. at N11 and "t. (ude &edical at N@1. ' good ;BI and market price signals the confidence the market places on the company and should signal investors to put their bets on this one. 's a part of the medical sector, Cyberonics Inc. is one of the companies whose would not be compromised as much even with economic dips in the market because of the consistent demand for medical aids and services. CyberonicsL strength in the stock market was demonstrated with analystsL continuous placement of the company in their list of top stocks. <ith Canaccord Fenuity, amongst other notable analysts, raising the companyLs target price to N6,, Cyberonics positions itself among A .ealthcare "tocks Dositioned 2or .igh Frowth and @ ;allying &edical 3evice "tocks <ith "trong "ources Bf Drofitability and finishes with an outstanding + out of )/ ;euters analysts rating it as 9uy and Butperform.